Foghorn’s Phase I AML/MDS trial on FDA partial clinical hold due to subject death
No new subjects will be enrolled in the trial until the FDA lifts the partial clinical hold.

No new subjects will be enrolled in the trial until the FDA lifts the partial clinical hold.
The company received FDA clearance for the IND application to initiate the trial.
Under the collaboration, the first trial site will be opened at a new facility of Headlands in Brownsville, Texas, US.
eConsent offers the flexibility to include differences in regulations by country, consent methods, consent types and device needs.
Treatment with investigational drug Ampligen for a minimum of 12 weeks offered a decline in fatigue in long Covid patients.
The Phase I trial will analyse for safety and immunogenicity of the mRNA HIV vaccine antigen in African populations.
The trial will analyse BIO 300’s ability to alleviate long-term pulmonary damage in Covid-19 survivors.
The trial will assess the safety and tolerability of oncolytic virus CF33-hNIS as monotherapy or along with pembrolizumab.